Predictive Parameters of a Worse Prognosis in Patients with G2 Neuroendocrine Tumors Treated with Peptide Radio Receptorial Therapy

被引：0
|
作者：
Jandric, J. [1 ]
Laffi, A. [1 ]
Muraglia, L. [1 ]
Zanca, R. [1 ,2 ]
Rodari, M. [1 ]
Evangelista, L. [1 ,2 ]
机构：
[1] IRCCS Humanitas Res Hosp, Rozzano, Italy
[2] Humanitas Univ, Pieve Emanuele Milano, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0598
引用
收藏
页码：S669 / S670
页数：2
相关论文
共 50 条
  • [41] Lutetium 177-DOTATATE Therapy in Progressive Metastatic Well-Differentiated G1/G2 Neuroendocrine Tumors: Review of the University of Kentucky's Post-FDA Approval PRRT Program
    Chacko, Charles Andrew
    Chauhan, Aman
    El Khouli, Riham
    Anthony, Lowell
    PANCREAS, 2020, 49 (03) : 465 - 465
  • [42] A systematic literature review of studies assessing first-line (1L) treatments in patients with advanced, grade 2/3 (G2/G3) gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Capdevila, Jaume
    Deshayes, Emmanuel
    Navalkissoor, Shaunak
    Srirajaskanthan, Raj
    Folitar, Ilya
    Lovelle, Marcos
    Soni, Deepali
    Lakkakula, Udaya Sri
    Joshi, Parth
    Pathak, Purnima
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 663 - 663
  • [43] Long-Acting Somatostatin Analogue (LA-SSA) Treatment Durations in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden
    Berthon, A.
    Granfeldt, D.
    Bjorstad, A.
    Marlow, T.
    Dinet, J.
    Myrenfors, P.
    Lesen, E.
    Bjorholt, I
    Elf, A. K.
    Johanson, V
    NEUROENDOCRINOLOGY, 2018, 106 : 61 - 61
  • [44] Long-Acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden
    Berthon, A.
    Bjorstad, A.
    Granfeldt, D.
    Marlow, T.
    Dinet, J.
    Myrenfors, P.
    Lesen, E.
    Bjorholt, I
    Elf, A. K.
    Johanson, V
    NEUROENDOCRINOLOGY, 2018, 106 : 134 - 134
  • [45] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors The First US Phase 2 Experience
    Delpassand, Ebrahim S.
    Samarghandi, Amin
    Zamanian, Sara
    Wolin, Edward M.
    Hamiditabar, Mohammadali
    Espenan, Gregory D.
    Erion, Jack L.
    O'Dorisio, Thomas M.
    Kvols, Larry K.
    Simon, Jaime
    Wolfangel, Robert
    Camp, Arthur
    Krenning, Eric P.
    Mojtahedi, Alireza
    PANCREAS, 2014, 43 (04) : 518 - 525
  • [46] Clinical Characteristics of 144 Patients (pts) Included in a Multidisciplinary Group, with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) G2 (WHO 2010). Grupo Argentum
    O'Connor, J. M.
    Pesce, V.
    Bestanti, C.
    Marmissolle, F.
    Price, P.
    Cabanne, A.
    Kujaruk, M.
    Domenichini, E.
    Belli, S.
    Mariani, J.
    Roca, E.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 242 - 242
  • [47] Clinical Use of Lanreotide AG as Initial Therapy in Patients with Advanced, Non-Resectable Well (G1) and Moderate (G2) Differentiated Pancreatic Neuroendocrine Neoplasms (p-NEN)
    Cwikla, J.
    Kolasinska-Cwikla, A.
    Lewczuk-Myslinska, A.
    Palucki, J.
    Roszkowska-Purska, K.
    Kidd, M.
    Bodei, L.
    Modlin, I
    NEUROENDOCRINOLOGY, 2018, 106 : 187 - 187
  • [48] Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).
    Capdevila, Jaume
    Fazio, Nicola
    Lopez, Carlos Lopez
    Teule, Alex
    Valle, Juan W.
    Tafuto, Salvatore
    Custodio, Ana B.
    Reed, Nicholas
    Raderer, Markus
    Grande, Enrique
    Garcia-Carbonero, Rocio
    Jimenez-Fonseca, Paula
    Alonso, Vicente
    Antonuzzo, Lorenzo
    Spallanzani, Andrea
    Berruti, Alfredo
    Sevilla, Isabel
    Munoa, Adelaida La Casta
    Hernando-Cubero, Jorge
    Ibrahim, Toni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] 68Ga-DOTANOC uptake pattern as a prognostic factor in patients with non-functional well-differentiated G1/G2 pancreatic neuroendocrine tumours treated with 177Lu-DOTATATE
    Sampaio, I. L.
    Ferreira, G.
    Fonseca, L.
    Pedro, J.
    Gouveia, P.
    Castro, S.
    Duarte, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S637 - S637
  • [50] Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM)
    Thakral, Parul
    Sen, Ishita
    Pant, Vineet
    Gupta, Santosh Kumar
    Dureja, Sugandha
    Kumari, Jyotsna
    Kumar, Sunil
    Pallavi
    Malasani, Vindhya
    BRITISH JOURNAL OF RADIOLOGY, 2018, 91 (1091):
12345